Becton Dickinson and Co vs Davita Inc — how do they compare? Becton Dickinson and Co trades at $154.29 (market cap $42.39B), while Davita Inc trades at $232 (market cap $15.12B). The key difference: Becton Dickinson and Co is far larger — about 2.8× Davita Inc's market cap, and Becton Dickinson and Co pays a 2.73% dividend while Davita Inc pays none. Which is the better fit depends on your goals.
| BDX | DVA | |
|---|---|---|
Market Cap | $42.39B | $15.12B |
Sector | Health | Health |
52-Week High | $185.39 | $235.71 |
52-Week Low | $135.49 | $103.87 |
Enterprise Value | $58.85B | $27.67B |
Dividend Yield | 2.73% | — |
Trailing returns across standard periods
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →